礼来(LLY)
icon
搜索文档
Eli Lilly's Alzheimer's Drug Obtains FDA Approval. Here's Why the Stock Isn't Taking Off.
The Motley Fool· 2024-07-13 18:31
The news likely didn't come as a big surprise to investors.Eli Lilly (LLY 1.53%) received some great news from regulators last week: Its Alzheimer's treatment obtained the green light from the Food and Drug Administration (FDA).The new drug, Kisunla, has the potential to be a blockbuster for the company and generate billions in revenue. But despite the recent approval, Eli Lilly's stock isn't skyrocketing.Normally, when a healthcare stock receives positive news surrounding a much-anticipated treatment, ther ...
Did Eli Lilly Just Get a Leg Up on Novo Nordisk?
The Motley Fool· 2024-07-13 17:30
Eli Lilly's latest milestone sets it apart from its rival Novo Nordisk.Pharmaceutical giant Eli Lilly (LLY 1.53%) has gotten off to an incredible start in 2024.The company's diabetes and obesity care treatments, Mounjaro and Zepbound, continue to support unprecedented growth for Lilly in a heated race with its rival Novo Nordisk, the maker of glucagon-like peptide 1 (GLP-1) agonists Ozempic, Wegovy, Rybelsus, and Saxenda.Although GLP-1 medications are in the spotlight for Lilly, investors should be keen to ...
Should You Buy Eli Lilly Stock After Another Major Win?
The Motley Fool· 2024-07-12 18:13
It was a buy even before this development."Winners keep winning." Whatever one thinks of this adage, it certainly seems to apply to Eli Lilly (LLY -0.60%). The pharmaceutical giant has been on a tear, racking up important clinical and regulatory victories in the past few years. The result: Eli Lilly has soundly crushed the market in the past five years, and the company is at it again. A recent regulatory win further improved Eli Lilly's prospects. Let's take a closer look.Eli Lilly succeeds where many other ...
Better Growth Play: Eli Lilly vs. Vanguard Growth Index Fund ETF Shares
The Motley Fool· 2024-07-11 17:30
Both equities have been incredible growth plays of late.Large-cap U.S. stocks have been on a relentless bull run for the better part of the last two years. Despite sticky inflation, geopolitical turmoil, and historically high valuations for most major indexes, U.S. large caps have shown no signs of cooling off in 2024.In line with this trend, Eli Lilly (LLY 0.78%), a major player in metabolic disorders, cancer, immunology, and neuroscience, has seen its shares rise nearly 60% this year. Meanwhile, the Vangu ...
3 Pharma Stocks That Could Make Your Grandchildren Rich
Investor Place· 2024-07-11 02:34
Pharmaceutical stocks have not set the world on fire, with a few exceptions. Since the pandemic ended, pharma stocks have largely fallen out of favor with investors amid declining sales and mixed financial results. Consequently, the S&P Pharmaceuticals Index is down 5% this year compared to an 18% gain in the benchmark S&P 500 Index.While the poor performance is disappointing, a select few pharma stocks are defying the downward trend and actually rising. Several others look extremely promising and undervalu ...
Novo Nordisk Falls as Study Says Eli Lilly Weight-Loss Ingredient More Effective
Investopedia· 2024-07-10 01:55
Key TakeawaysAmerican depositary receipts of Novo Nordisk fell Tuesday while shares of Eli Lilly rose following results of a new study.A JAMA Internal Medicine study published Monday found that the active ingredient in Eli Lilly's Mounjaro and Zepbound caused greater weight loss than that of Novo Nordisk's Ozempic and Wegovy.The weight-loss drugs have substantially boosted both companies' earnings and stock prices over the last two years as demand has surged. The stock price of a pair of pharmaceutical comp ...
Study Shows Lilly's (LLY) Obesity Drug More Effective Than NVO's
ZACKS· 2024-07-10 01:05
Data from a new study show that patients who received Eli Lilly’s (LLY) Mounjaro (tirzepatide) significantly lost more weight than those who received Novo Nordisk’s (NVO) Wegovy (semaglutide). Both drugs are approved to treat obesity in adults.While the medications were shown to be effective in achieving weight loss, the findings indicate that Mounjaro may be more beneficial. After three months, patients taking the Lilly drug lost an average of 5.9% of their body weight compared with 3.6% for those on Novo’ ...
Eli Lilly (LLY) to Buy Morphic for $3.2B, Boost IBD Presence
ZACKS· 2024-07-09 23:20
Eli Lilly and Company (LLY) announced a definitive agreement to acquire Waltham, MA-based small biotech Morphic Therapeutics (MORF) for approximately $3.2 billion. The acquisition will expand Lilly’s pipeline in immunology, a core area for the company, by adding Morphic’s oral integrin therapies for treating serious chronic diseases.Morphic's lead pipeline candidate is MORF-057, an oral α4β7 inhibitor with the potential to improve outcomes in treating inflammatory bowel disease (IBD). The integrin, α4β7, ha ...
Is Eli Lilly Stock a No-Brainer Buy After Its FDA Alzheimer's Disease Drug Win?
The Motley Fool· 2024-07-09 18:15
No matter how you look at it, the FDA approval of Kisunla is big for Eli Lilly.How does Eli Lilly (LLY 0.38%) follow up on gains of close to 60% in 2023 and so far in 2024? By winning a major U.S. Food and Drug Administration (FDA) approval.Last week, the FDA approved Lilly's Kisunla (donanemab) in treating early symptomatic Alzheimer's disease. Is Eli Lilly stock a no-brainer buy after this key FDA approval? How big is Lilly's FDA win?There are now eight FDA-approved treatments for Alzheimer's disease. Tha ...
Eli Lilly Rose More Than 50% So Far This Year. Can It Soar Past $1,000 in the 2nd Half?
The Motley Fool· 2024-07-09 17:15
This pharma company is posting double-digit revenue growth.The stocks that led gains in the S&P 500 Index in the first half primarily were in the field of tech, operating in the high-growth area of artificial intelligence (AI). But an exception emerged, and this company operates in the generally slower-but-steady growth business of pharmaceuticals. I'm talking about Eli Lilly (LLY 0.38%). The pharma giant's shares soared 55% in the first half as the company posted double-digit revenue growth -- and amid exc ...